Madrigal Pharmaceuticals Company Leadership
| MDGL Stock | USD 346.40 4.78 1.40% |
Madrigal Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Madrigal Pharmaceuticals suggests that most insiders are panicking. Madrigal Pharmaceuticals employs about 528 people. The company is managed by 19 executives with a total tenure of roughly 1232 years, averaging almost 64.0 years of service per executive, having 27.79 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-03-05 | Robert E Waltermire | Disposed 14113 @ 341.32 | View | ||
| 2025-02-28 | Robert E Waltermire | Disposed 1227 @ 341.07 | View | ||
| 2025-02-27 | James M Daly | Disposed 15470 @ 347.45 | View | ||
| 2025-01-24 | William John Sibold | Disposed 1584 @ 335.24 | View | ||
| 2025-01-17 | Shannon T Kelley | Disposed 277 @ 273.41 | View | ||
| 2024-12-03 | Fred B Craves | Disposed 3600 @ 315.31 | View | ||
| 2024-11-25 | Fred B Craves | Disposed 3400 @ 350.3 | View | ||
| 2024-11-01 | Richard S Levy | Disposed 5000 @ 300.94 | View | ||
| 2024-09-09 | William John Sibold | Disposed 6363 @ 243.83 | View | ||
| 2024-06-14 | Robert E Waltermire | Disposed 1900 @ 280 | View | ||
| 2024-06-12 | Robert E Waltermire | Disposed 2000 @ 285 | View | ||
| 2024-05-21 | Robert E Waltermire | Disposed 1036 @ 231.34 | View | ||
| 2024-05-14 | Fred B Craves | Disposed 22489 @ 212.88 | View | ||
| 2024-04-08 | Rebecca Taub | Disposed 2676 @ 245.99 | View |
Monitoring Madrigal Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Madrigal |
Madrigal Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Madrigal Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Madrigal will maintain a workforce of about 530 employees by April 2025.Madrigal Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3698) % which means that it has lost $0.3698 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8035) %, meaning that it created substantial loss on money invested by shareholders. Madrigal Pharmaceuticals' management efficiency ratios could be used to measure how well Madrigal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.47. The value of Return On Capital Employed is expected to slide to -0.6. At this time, Madrigal Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year.Common Stock Shares Outstanding is expected to rise to about 22.3 M this year, although the value of Net Loss is projected to rise to (252.5 M).
Madrigal Pharmaceuticals Workforce Comparison
Madrigal Pharmaceuticals is regarded fourth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 5,778. Madrigal Pharmaceuticals holds roughly 528 in number of employees claiming about 9% of equities under Health Care industry.
Madrigal Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (2.59) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.65.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.78 | 0.87 |
|
|
Madrigal Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Madrigal Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Madrigal Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Madrigal Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 0.3731 | 25 | 67 | 195,384 | 190,891 |
| 2024-12-01 | 0.1667 | 2 | 12 | 10,000 | 27,688 |
| 2024-09-01 | 0.5 | 2 | 4 | 13,035 | 25,532 |
| 2024-06-01 | 0.2677 | 34 | 127 | 293,092 | 643,750 |
| 2024-03-01 | 2.8571 | 20 | 7 | 1,168,283 | 26,340 |
| 2023-12-01 | 5.5556 | 150 | 27 | 2,106,294 | 1,591,794 |
| 2023-03-01 | 0.3125 | 10 | 32 | 137,828 | 84,300 |
| 2022-12-01 | 0.0294 | 1 | 34 | 7,000 | 74,000 |
| 2022-03-01 | 6.0 | 6 | 1 | 278,750 | 19,000 |
| 2021-12-01 | 0.1667 | 1 | 6 | 5,000 | 1,648,344 |
| 2020-09-01 | 0.0833 | 1 | 12 | 20,000 | 3,150,920 |
| 2020-06-01 | 0.8571 | 6 | 7 | 36,000 | 884,472 |
| 2020-03-01 | 4.0 | 4 | 1 | 158,000 | 16,000 |
| 2019-06-01 | 3.0 | 6 | 2 | 70,000 | 5,500 |
| 2018-12-01 | 1.5 | 6 | 4 | 20,000 | 45,000 |
| 2018-09-01 | 1.0 | 1 | 1 | 20,000 | 20,000 |
| 2018-06-01 | 1.125 | 9 | 8 | 137,391 | 651,582 |
| 2016-09-01 | 7.75 | 31 | 4 | 9,574,071 | 31,348 |
| 2015-12-01 | 0.1395 | 6 | 43 | 1,013,722 | 17,014,412 |
| 2015-09-01 | 11.5 | 23 | 2 | 4,859,257 | 4,120,854 |
| 2015-06-01 | 3.0 | 6 | 2 | 10,186,289 | 829,146 |
| 2014-12-01 | 2.0 | 4 | 2 | 900,000 | 0.00 |
| 2014-09-01 | 21.0 | 21 | 1 | 1,653,522 | 0.00 |
| 2014-03-01 | 0.4545 | 5 | 11 | 409,708 | 247,580 |
| 2013-12-01 | 7.0 | 7 | 1 | 5,358,333 | 0.00 |
| 2013-03-01 | 2.25 | 18 | 8 | 922,423 | 92,250 |
| 2012-12-01 | 4.5 | 9 | 2 | 2,697,235 | 3,969 |
| 2012-06-01 | 1.4 | 7 | 5 | 1,562,340 | 1,928,680 |
| 2012-03-01 | 2.3333 | 7 | 3 | 1,613,499 | 13,796 |
| 2011-12-01 | 4.0 | 8 | 2 | 232,559 | 500,000 |
| 2011-06-01 | 1.5 | 3 | 2 | 1,581,493 | 20,000 |
| 2011-03-01 | 2.75 | 11 | 4 | 481,469 | 28,708 |
| 2010-12-01 | 1.5 | 3 | 2 | 1,615,923 | 0.00 |
| 2010-09-01 | 8.0 | 16 | 2 | 185,485 | 4,000 |
| 2009-09-01 | 6.3333 | 19 | 3 | 140,716 | 82,760 |
| 2008-03-01 | 4.5 | 9 | 2 | 435,760 | 75,000 |
| 2007-12-01 | 0.6667 | 2 | 3 | 33,125 | 28,125 |
| 2007-03-01 | 0.45 | 18 | 40 | 4,904,617 | 7,538,490 |
Madrigal Pharmaceuticals Notable Stakeholders
A Madrigal Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Madrigal Pharmaceuticals often face trade-offs trying to please all of them. Madrigal Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Madrigal Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William Sibold | President CEO | Profile | |
| Mardi Dier | Principal CFO | Profile | |
| Justin Drinkwine | Senior VP | Profile | |
| Thomas Hare | Senior Management | Profile | |
| Remy Sukhija | VP Officer | Profile | |
| PharmD MBA | Senior Affairs | Profile | |
| Mark Underwood | Senior Operations | Profile | |
| Ronald Filippo | Chief Officer | Profile | |
| Rebecca MD | Chief Founder | Profile | |
| Robert Waltermire | Chief Officer | Profile | |
| Carole Huntsman | Chief Officer | Profile | |
| Paul MD | Chairman CEO | Profile | |
| Edward Chiang | Senior Operations | Profile | |
| Clint Wallace | Chief Officer | Profile | |
| Tina Ventura | Chief Officer | Profile | |
| Kianoush Motesharei | Senior Development | Profile | |
| Shannon Kelley | General Counsel | Profile | |
| Alex Howarth | Executive Officer | Profile | |
| Brian JD | Senior Counsel | Profile |
About Madrigal Pharmaceuticals Management Performance
The success or failure of an entity such as Madrigal Pharmaceuticals often depends on how effective the management is. Madrigal Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Madrigal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Madrigal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.62) | (0.59) |
Madrigal Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Madrigal Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Madrigal Pharmaceuticals within its industry.Madrigal Pharmaceuticals Manpower Efficiency
Return on Madrigal Pharmaceuticals Manpower
| Revenue Per Employee | 341.2K | |
| Revenue Per Executive | 9.5M | |
| Net Loss Per Employee | 882.4K | |
| Net Loss Per Executive | 24.5M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 45.5M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.